Re-expansion pulmonary oedema (RPE) is an uncommon complication that occurs when a collapsed lung suddenly re-expands, resulting in an osmotic shift of fluid from the blood vessels into the air spaces ...

Medications for pulmonary embolism may decrease the size of blood clots, help dissolve them, or reduce the risk of recurrence. All of these medications carry the risk of bleeding. A pulmonary ...

Findings from the first international randomized controlled trial to compare patient outcomes following treatment with ...

Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today the US Food and Drug Administration has approved its ...

(Nasdaq:NARI) today announced positive results from its prospective PEERLESS trial for the FlowTriever system.

Shatti, head of the Cardiac Catheterization Unit at Al-Dabous Center at Al-Adan Hospital, announced that the hospital has ...

The trial adds much-needed randomized data to an area where it’s been lacking. Questions about methods muddy interpretation.

Over the past century, heart operations that once were unthinkable have become commonplace. Thousands of times a day, ...

Akura Medical, a Shifamed portfolio company, announced today that the FDA granted its Katana system investigational device exemption (IDE).

Jupiter Endovascular, Inc. announced that the first patient has been treated in the SPIRARE II United States pivotal study of ...

The FlowTriever system is 510(k)-Cleared by FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium. Inari Medical NewsMORE Related Stocks ...